Publication:
Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials

Simple item page
dc.contributor.authorRaimondi, A.
dc.contributor.authorMorano, F.
dc.contributor.authorTrarbach, T.
dc.contributor.authorKarthaus, M.
dc.contributor.authorLonardi, S.
dc.contributor.authorFruehauf, S.
dc.contributor.authorCremolini, C.
dc.contributor.authorGraeven, U.
dc.contributor.authorBittoni, A.
dc.contributor.authorMueller, L.
dc.contributor.authorBianchi, A. Sartore
dc.contributor.authorAranda, E.
dc.contributor.authorBoige, V.
dc.contributor.authorStintzing, S.
dc.contributor.authorDi Bartolomeo, M.
dc.contributor.authorKoenig, A.
dc.contributor.authorPietrantonio, F.
dc.contributor.authorModest, D.
dc.contributor.authoraffiliation[Raimondi, A.] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
dc.contributor.authoraffiliation[Morano, F.] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
dc.contributor.authoraffiliation[Pietrantonio, F.] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
dc.contributor.authoraffiliation[Trarbach, T.] Univ Hosp Essen, Rehazentrum Meer, Bad Zwischenahn, Essen, Germany
dc.contributor.authoraffiliation[Trarbach, T.] Univ Hosp Essen, Dept Med Oncol, West German Canc Ctr, Westdeutsches Turmozentrum, Essen, Germany
dc.contributor.authoraffiliation[Lonardi, S.] Munich Hosp Neuperlach, Dept Hematol & Oncol, Munich, Germany
dc.contributor.authoraffiliation[Fruehauf, S.] Veneto Inst Oncol IRCCS, Med Oncol, Padua, Italy
dc.contributor.authoraffiliation[Cremolini, C.] Dr Hancken Hosp, Stade, Germany
dc.contributor.authoraffiliation[Graeven, U.] Univ Pisa, Azienda Osped Univ Pisana, Med Oncol Unit, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
dc.contributor.authoraffiliation[Bittoni, A.] Kliniken Maria Hilf GmbH, Monchengladbach, Germany
dc.contributor.authoraffiliation[Bittoni, A.] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Med Oncol & Hematol Unit, Rozzano, Italy
dc.contributor.authoraffiliation[Mueller, L.] Oncol Practice Unter Ems, Leer, Germany
dc.contributor.authoraffiliation[Bianchi, A. Sartore] Univ Milan, Div Oncol, Grande Osped Metropolitano Niguarda, Milan, Italy
dc.contributor.authoraffiliation[Bianchi, A. Sartore] Univ Milan, Dept Oncol & Hematol, Milan, Italy
dc.contributor.authoraffiliation[Boige, V.] Univ Cordoba, Inst Maimonides Invest Biomed Cordoba, CIBERONC, Hosp Univ Reina Sofia,Inst Salud Carlos 3, Cordoba, Spain
dc.contributor.authoraffiliation[Stintzing, S.] Gustave Roussy, Villejuif, France
dc.contributor.authoraffiliation[Stintzing, S.] Charite Univ med Berlin, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany
dc.contributor.authoraffiliation[Stintzing, S.] Free Univ Berlin, Berlin, Germany
dc.contributor.authoraffiliation[Stintzing, S.] Humboldt Univ, Berlin, Germany
dc.contributor.authoraffiliationBerlin Inst Hlth, Berlin, Germany
dc.contributor.authoraffiliation[Di Bartolomeo, M.] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
dc.contributor.authoraffiliation[Pietrantonio, F.] Univ Med Gottingen, Dept Gastroenterol, Gottingen, Germany
dc.contributor.funderAmgen
dc.date.accessioned2023-05-03T14:40:46Z
dc.date.available2023-05-03T14:40:46Z
dc.date.issued2022-06-01
dc.description.abstractBackground: In metastatic colorectal cancer (mCRC), after a first-line induction with doublet/triplet chemotherapy plus bevacizumab, fluoropyrimidine+bevacizumab is the recommended maintenance option. The combination of anti-EGFR agents and chemotherapy is a guideline-endorsed first-line option for RAS/BRAF wild-type (wt) mCRC patients, but the optimal maintenance schedule has not been defined, yet. The Valentino trial showed that, after 4-month FOLFOX+panitumumab induction, singleagent panitumumab induced inferior progression-free survival (PFS) than FUFA+panitumumab, though slightly reducing toxicity. The Panama study demonstrated that, after 3-month FOLFOX+panitumumab induction, FUFA+panitumumab induced a significantly superior PFS than FUFA alone.
dc.identifier.citationRaimondi A, Morano F, Trarbach T, Karthaus M, Lonardi S, Fruehauf S, et al. SO-21 Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials. Annals Of Oncology [Internet]. 1 de junio de 2022;33:S366
dc.identifier.doi10.1016/j.annonc.2022.04.420
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753422011103/pdf
dc.identifier.urihttp://hdl.handle.net/10668/21914
dc.identifier.wosID823826500341
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.page.number366
dc.provenanceRealizada la curación de contenido 26/08/2024
dc.publisherElsevier
dc.relation.publisherversionhttps://www.annalsofoncology.org/article/S0923-7534(22)01110-3/fulltext
dc.rights.accessRightsopen access
dc.subjectPanitumumab
dc.subjectBevacizumab
dc.subjectProto-oncogene proteins B-raf
dc.subject.decsHumanos
dc.subject.decsNeoplasias colorrectales
dc.subject.decsNeoplasias del colon
dc.subject.decsNeoplasias del recto
dc.subject.decsSupervivencia sin progresión
dc.subject.meshHumans
dc.subject.meshProgression-free survival
dc.subject.meshColorectal neoplasms
dc.subject.meshColonic neoplasms
dc.subject.meshRectal neoplasms
dc.titleOptimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number33
dc.wostypeMeeting Abstract
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía